News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Lynette Smith, PhD

Articles by Lynette Smith, PhD

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

ByOmar K. Abughanimeh, MBBS,Nicole A. Shonka, MD,Jane Meza, PhD,Lynette Smith, PhD,Irfan A. Vaziri, MD,Mehmet Sitki Copur, MD,Robin High, MBA,Kimberly Shields, BSN, RN,Holly DeSpiegelaere, BSN, RN,Anne Kessinger, MD,Apar Kishor Ganti, MD, MS

August 13th 2025

This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.

Latest Updated Articles

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
Published: August 13th 2025 | Updated:
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
Published: October 30th 2025 | Updated:

Trending on CancerNetwork

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

© 2025 MJH Life Sciences^®

All rights reserved.